作为一个有前途的治疗点的ADAM17:从结构基础到人类疾病中的抑制剂发现
Lisa Liu1, Erkang Tian1, Shuqi Quan1
1State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Frontiers in pharmacology
|October 6, 2025
概括
分解蛋白和金属蛋白酶17 (ADAM17) 是一种关键蛋白酶,涉及各种疾病. 这篇评论详细介绍了ADAM17的细节.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 病理生理学 病理生理学
背景情况:
- ADAM17是一种跨膜蛋白酶,对于分离膜蛋白至关重要.
- ADAM17在生理过程和疾病发病过程中发挥作用.
- 有证据表明ADAM17与炎症,癌症以及心血管/神经退行性疾病有关.
研究的目的:
- 为提供ADAM17.的全面概述.
- 为了强调ADAM17在人类疾病中的作用.
- 讨论针对ADAM17的治疗策略.
主要方法:
- 对ADAM17的分子结构和功能进行文献综述.
- 对ADAM17在疾病发病过程中的参与进行分析.
- 审查当前和新兴的针对ADAM17的治疗药物.
主要成果:
- 详细介绍了ADAM17的结构和功能.
- 突出了ADAM17在各种疾病状态中的影响.
- 介绍了小分子抑制剂,单克隆抗体和针对ADAM17的调控蛋白的进展.
结论:
- ADAM17是多种疾病的重要治疗点.
- 了解ADAM17结构是开发有效抑制剂的关键.
- 本综述指导了未来针对ADAM17相关疾病的药物发现工作.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
G Protein-coupled Receptors
16.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.5K


